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Abstract
 
In spite of high frequencies of metal allergies, the structural basis for major histocompatibility
complex (MHC)-restricted metal recognition is among the unanswered questions in the field
of T cell activation. For the human T cell clone SE9, we have identified potential Ni contact
sites in the T cell receptor (TCR) and the restricting human histocompatibility leukocyte anti-
gen (HLA)-DR structure. The specificity of this HLA-DR–promiscuous VA22/VB17
 
  
 
TCR
is primarily harbored in its 
 
  
 
chain. Ni reactivity is neither dependent on protein processing in
antigen-presenting cells nor affected by the nature of HLA-DR–associated peptides. However,
SE9 activation by Ni crucially depends on Tyr
 
29 
 
in CDR1
 
 
 
, an 
 
N
 
-nucleotide–encoded Tyr
 
94
 
in CDR3
 
 
 
, and a conserved His
 
81 
 
in the HLA-DR 
 
  
 
chain. These data indicate that labile,
nonactivating complexes between the SE9 TCR and most HLA-DR/peptide conjugates
might supply sterically optimized coordination sites for Ni ions, three of which were identified
in this study. In such complexes Ni may effectively bridge the TCR 
 
  
 
chain to His
 
81 
 
of most
DR molecules. Thus, in analogy to superantigens, Ni may directly link TCR and MHC in a
peptide-independent manner. However, unlike superantigens, Ni requires idiotypic, i.e.,
CDR3
 
 
 
-determined TCR amino acids. This new type of TCR–MHC linkage might explain
the high frequency of Ni-reactive T cells in the human population.
Key words: hypersensitivity • antigen presentation • hapten • T cell receptor • mutation
 
Introduction
 
Studies dealing with the characterization of antigenic
epitopes for T cells have primarily focused on protein an-
tigens. However, T cells may also be triggered by a vast
variety of low molecular haptens that frequently result in
allergic hyperreactivities (1–3). A subclass of these allergens
consists of metals that might be encountered repeatedly via
cutaneous, respiratory, oral, or intramuscular routes. These
contacts may result in immune-mediated pathologies such
as contact hypersensitivity to Au, Be, Co, and in particular
to Ni (1, 4), pulmonary granulomatous disease, also called
chronic beryllium disease (5), cobalt-induced hard metal
lung disease (6), or nephropathy as a result of treatment
with gold salts (7). Contact allergy or granulomas may also
be caused by aluminium hydroxide, a commonly used ad-
juvant in vaccines. Thus, 620 cases of itching granulomas
and contact allergy to aluminium were recently reported
for children undergoing diphtheria-tetanus-pertussis vacci-
nation (8). Although the capacity of these metals to induce
MHC-restricted T cell activation is well established (9), the
nature of the allergenic epitopes recognized by metal-spe-
cific T cells remains unknown in most cases.
Several models have been proposed to explain the acti-
vation of metal-reactive T cells: (a) analogous to typical
haptens such as TNP or penicillin (1), metal-specific TCR
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may react to determinants formed by a complex of metal
ions with MHC-embedded self-peptides (9, 10), (b) TCR
may recognize metal-modified amino acid residues of the
MHC molecule itself or metal-provoked conformational
changes in the MHC (11), and (c) metals may affect the
processing of self-antigens, resulting in T cells reactive to
cryptic self-peptides (12, 13).
None of these models is mutually exclusive and each
metal may use several pathways to activate T cells. The first
and third of these models have been suggested for Ni- (10,
13) as well as for Au-reactive T cells (9, 12). The second
model is favored in the case of Co (hard metal lung disease)
and Be (chronic beryllium disease) where the development
of disease has been correlated to HLA-DPB1 alleles ex-
pressing glutamate in position 69 of the DP 
 
  
 
chain (14–
16). Glu
 
69 
 
has been implicated in the binding of Be (14) as
well as of Co (11).
We have chosen to study nickel as a model of metal-
induced T cell activation because Ni represents one of the
most common contact allergens in humans (4). This study
concentrates on one particular CD4
 
 
 
, Ni-reactive human
T cell clone, clone SE9. This clone belongs to a group of
TCRBV17-expressing T cells that we and others found
overrepresented among Ni-specific CD4
 
  
 
T cells of pa-
tients suffering from particularly severe Ni contact hyper-
sensitivity (17, 18). However, unlike VB17
 
  
 
clones from
other patients, the TCR of clone SE9 exhibited a domi-
nance of its TCR 
 
  
 
chain in determining antigen specific-
ity. Its 
 
  
 
chain retained HLA-DR–restricted Ni reactivity
even upon pairing with unrelated 
 
  
 
chains (19), indicating
that in this case the usage of BV17 is not related to Ni spec-
ificity. We took advantage of this apparently selective local-
ization of Ni contact sites in the TCR 
 
  
 
chain to investi-
gate the relevance of the different activation models listed
above in the case of clone SE9.
 
Materials and Methods
 
Antigens, Reagents, and Media.
 
If not specified otherwise, re-
agents were used at the following concentrations: 10
 
 
 
4 
 
M
NiSO
 
4 
 
  
 
6H
 
2
 
O, 1 
 
 
 
g/ml phytohemagglutinin (PHA-P;
Murex), 20 ng/ml staphylococcal enterotoxin B (SEB;
 
* 
 
Serva),
and rat spleen Con A supernatant (10%) served as a source of IL-2
to maintain CTLL cells. Growth medium for T cell hybridomas
(RPMI-FCS) was RPMI 1640 supplemented with 2 mM 
 
l
 
-glu-
tamine, 5 
 
  
 
10
 
 
 
5
 
 M 2-mercaptoethanol (Roth), 10% heat-inac-
tivated FCS, and 10 mM Hepes (GIBCO BRL). Culture condi-
tions for human T cell clones have been previously described
(19, 20). Monoclonal antibodies against HLA-DR (L243;
American Type Culture Collection [ATCC]), HLA-DP (B7.21;
ATCC), or HLA-DQ (SVPL3; ATCC) were used as 1:10 di-
luted culture supernatants. Stainings for flow cytometry were
performed with FITC-conjugated anti-huV
 
 
 
17 (E17.5F3.15.13;
Beckman Coulter).
 
Cell Lines and T Cell Clones.
 
The Ni-specific human T cell
clone SE9 and the murine hybridoma T913 carrying the SE9
TCR have been previously described (19). The T cell donor SE
expressed HLA-DRB1
 
*
 
0101, DRB1
 
*
 
1501, and DR51. The
TCR
 
  
 
huCD4
 
  
 
murine T cell hybridoma 54
 
 
 
17 (21) was pro-
vided by O. Acuto (Institut Pasteur, Paris, France). HLA-DR
homozygous B cell lines JESTHOM (International Histocompat-
ibility Workshop [IHW] no. 9004, DRB1
 
*
 
0101), HOM-2 (IHW
no. 9005, DRB1
 
*
 
0101), WT47 (IHW no. 9063, DRB1
 
*
 
1302,
DR52), and SWEIG (IHW no. 9037, DRB1
 
*
 
1101, DR52) were
from the IHW. Mouse fibroblasts transfected with human HLA-
DRB1
 
*
 
0101, DRB1
 
*
 
0401, DRB1
 
*
 
1501, or DR53, designated as
L-DR1 (L544.H8), L-DR4 (L243.6), L-DR15 (L466.1), and
L-DR53 (L257.6), were obtained from F. Sinigaglia (Roche
Ricerce, Milano, Italy). The mouse fibroblast cell line Dap-3
(L cells) and wild-type or mutated HLA-DR1 liter cell transfec-
tants (22, 23) as well as the DR1 cotransfectants of 293 cells with
wild-type or mutated invariant chain (Ii; 24) have been previ-
ously described.
 
Expression Vectors for Wild-type and Mutated TCR.
 
The con-
structs for the CDR2
 
  
 
mutated or wild-type TCR 
 
  
 
genes were
cloned into the pV2–15
 
 
 
 vector (25) and transfected into 54
 
 
 
17
cells by electroporation as previously described (19). Mutation of
the CDR2
 
  
 
amino acids Asp
 
53 
 
and Asp
 
54 
 
to Ala was obtained by
overlapping PCR as previously described (19) using the follow-
ing complementary primer pair (mutated nucleotides underlined,
only sense orientation shown): GCCACGAAGGCTGCTGC-
CAAGGGAAG. For mutations in CDR1 and 3, cDNA’s coding
for TCR 
 
  
 
and 
 
  
 
chains were amplified by RT-PCR from RNA
of hybridoma T913 using primers EcoHVA22 liter (sense)
AAACCGgaattcCGGAGGAATGAACTATTCTCCAGG (EcoRI
site in lower case) and CAendBam (antisense) TTCTCGCggatc-
cGCGCAGACCTCAACTGGAC (BamHI site in lower case).
Upon cloning into pCR
 
®
 
-Blunt (Invitrogen), inserts were se-
quenced using the Big Dye sequencing kit (Applied Biosystems).
Sequences were read on a 310 Genetic Analyzer (Applied Biosys-
tems). Using the QuickChange Site-Directed Mutagenesis Kit
(Stratagene) and appropriate mutation primers (see below), point
mutations were introduced into the 
 
  
 
chain’s CDR1 and 3 se-
quences. All 
 
  
 
chain constructs, including the wild-type T913 
 
 
 
chain, were then excised with EcoRI and BamHI and recloned
into the pLXSN retroviral vector (neomycin resistance) as de-
scribed by Backstrom et al. (26) and Naeher et al. (27). Corre-
spondingly, the wild-type T913 
 
  
 
chain was amplified by
RT-PCR from T913 RNA using the primers EcoHVB17 liter
(sense) AAACCGgaattcCGGAGGAATGAGCAACCAGGTGCT
and CB2endBam (antisense) TTCTCGCggatccGCGCATGTC-
TCAGGAATTTTTTTT, and cloned into pLXSP (puromycin
resistance; reference 27). We used the BOSC packaging cell line
and followed published procedures (26) to express the various
TCR 
 
   
 
combinations in 54
 
 
 
17 hybridoma cells. TCR
 
  
 
cell
lines were cloned by limiting dilution and assayed for IL-2
responsiveness to SEB or NiSO
 
4
 
. Sequencing primers were
huLV
 
 
 
17 sense (ATGAGCAACCAGGTGCTCTGC), huV
 
 
 
17
sense (TTTCAGAAAGGAGATATAGCT), huV
 
 
 
22 sense (CCT-
CCTGAAAGCCACGAAGGCTGA), C
 
  
 
antisense (TGTCC-
TGAGACCGAGGATCT), murine C
 
  
 
antisense (TGATGGC-
TCAAACAAGGAGAC), as well as commercial M13f and M13r
primers (Invitrogen). Mutation primers (only sense primers shown,
mutated nucleotides underlined) were for CDR1: Mut-
VA22CDR1G-P s: GTACACAGCCACACCATACCCTTCC;
MutVA22CDR1T-A s: GTACACAGCCGCAGGATACCC-
TTC; MutVA22CDR1Y-A s: GCCACAGGAGCCCCTTCC-
CTTTTC; MutVA22CDR1Y-H s: CACAGCCACAGGAC-
ACCCTTCC. For CDR3: MutVA22CDR3
 
 
 
AvG s: CTTC-
 
*
 
Abbreviations used in this paper: 
 
Ii, invariant chain; SEB, staphylococcal
enterotoxin B.T
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TGTGCTCTGGCTGGGTATACCGGCAC; MutVA22CDR3G-P
s: CTTCTGTGCTCTGCCGTATACCGG; MutVA22CDR3T-A
s: GCTCTGGGGTATGCCGGCACTGCC; MutVA22CDR3Y-A s:
GTGCTCTGGGGGCTACCGGCACTG; MutVA22CDR3Y-F
s: TGTGCTCTGGGGTTTACCGGCA; MutVA22CDR3Y-H
s: TCTGTGCTCTGGGGCATACCGG.
 
IL-2 Secretion and Proliferation Assays.
 
Supernatants of 20 h
cocultures of 5 
 
  
 
10
 
4 
 
TCR transfectants and 5 
 
  
 
10
 
4 
 
X-irradiated
APCs with or without antigen were assayed for IL-2 by prolifera-
tion ([
 
3
 
H]thymidine incorporation) of an IL-2–dependent T cell
line as previously reported (28). Antigen-specific proliferation of
clone SE9 was determined by incorporation of [
 
3
 
H]thymidine as
previously described (19).
 
Results
 
Functional Characterization of Clone SE9 and Its TCR Ex-
pressed in the Mouse Hybridoma T913.
 
The Ni-reactive
human T cell clone SE9 was isolated from the peripheral
blood of donor SE. It expresses a VA22
 
 
 
/VB17
 
  
 
TCR, the
CD4 coreceptor, and the skin-homing molecule CLA (19
and unpublished data). Upon stimulation with NiSO
 
4
 
, SE9
secretes large amounts of IL-4 and IL-5, less IL-10 and IL-
2, and little to no IFN-
 
  
 
(unpublished data). Expression of
the variable parts of the SE9 TCR, fused to murine con-
stant 
 
  
 
and 
 
  
 
segments, together with human CD4 in the
mouse hybridoma 54
 
 
 
17 (21) resulted in the transfectant
T913, which possessed an identical pattern of specificity as
clone SE9 (19). Thus, the specificity of SE9 is defined ex-
clusively by its TCR.
Ni reactivity was determined by proliferation ([
 
3
 
H]thy-
midine incorporation) for clone SE9 and by IL-2 secretion
(proliferation of IL-2–dependent CTLL cells) for hy-
bridoma T913. Both stimuli were inhibited by mAbs to
HLA-DR, but not to HLA-DP nor HLA-DQ (Fig. 1, A
and B). However, in both cases, HLA-DR restriction was
highly promiscuous in that B cell lines from different do-
nors as well murine L cells transfected with a variety of in-
dividual HLA-DR alleles served as APC, albeit with vari-
able efficacy (Fig. 1 C; reference 19). These variations do
not relate to differences in MHC expression (unpublished
data), but probably reflect differences in the overall fit of
the SE9 TCR to the different HLA-DR alleles. In contrast,
HLA-DR53 was completely ineffective in mediating Ni
activation (Fig. 1 C).
TCR transfections had further shown that the T913 
 
 
 
chain could be combined with unrelated 
 
  
 
chains from
other human or even murine TCR without loss of its DR-
promiscuous Ni specificity (19). Although this implied that
the specificity of the T913 TCR is largely determined by
its AV22
 
  
 
  
 
chain, the activation is not due to a superanti-
gen-like coupling of HLA-DR by Ni to genomically de-
termined amino acids of AV22. A hybrid TCR containing
the T913 
 
  
 
chain together with the AV22
 
  
 
  
 
chain of a
different Ni-reactive clone (clone 3.14; reference 17) was
expressed in transfectants comparably to the original TCR
in hybridoma T913 (Fig. 2, A and B). Both hybridomas re-
sponded to SEB stimulation, but only the SE9 TCR was
activated by NiSO
 
4 
 
(Fig. 2, C and D). Hence, the Ni con-
Figure 1. Promiscuous HLA-DR restriction of hybridoma T913. (A)
Ni-specific proliferation of clone SE9 in the presence or absence of anti-
bodies against HLA-DR, HLA-DP, or HLA-DQ. (B) Effects of the same
antibodies on Ni-induced IL-2 production by hybridoma T913. (C)
Concentration-dependent Ni responses of T913 with HLA-DR–trans-
fected murine L cells or DR homozygous human B cells as APCs.
Figure 2. No superantigen-like usage of AV22 by nickel. Hybridoma
T913 (A and C) is compared with transfectant T314A/T913B (B and D)
combining the TCR   chain of T913 with the   chain of the Ni-reactive
human T cell clone 3.14 (reference 17). The T314   chain contains
AV22 like T913, but differs in joining and J sequences. (A and B) FACS®
staining with FITC-conjugated anti-huV 17 (shaded) compared with
isotype control (open) cells. (C and D) IL-2 production of T913 (C) or
T314 /T913  (D) on HOM-2 alone (open bars) with 2   10 4 M
NiSO4 (solid bars), or with 20 ng/ml SEB (hatched bars).T
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tacts apparently involve unique sequences of the T913  
chain, most likely within the V/J joining CDR3 loop.
Ni Recognition in the Absence of Antigen Processing. Clone
SE9 as well as the transfectant T913 both reacted to Ni in
the presence of glutaraldehyde-fixed as well as unfixed
APC (Fig. 3, A and B). Thus, antigen processing was not
required and cryptic self-peptides could be excluded as Ni-
induced determinants for clone SE9. However, SE9 cells
did not proliferate in response to APC (fixed or unfixed),
which had been preincubated with NiSO4 for 1 h and sub-
sequently washed (pulsed APC; Fig. 3 C). These findings,
indicating the necessity of permanent availability of Ni ions
in the medium, argue against the existence of preformed
Ni-MHC determinants for the SE9 TCR.
Ni Recognition Is Independent of the Nature of MHC-associ-
ated Peptides. The promiscuous HLA-DR restriction in-
fers that the nature of the DR-associated Ni epitopes might
be independent of the sequences of DR-associated pep-
tides. To directly address this question, we stimulated T913
cells in the presence of a series of human 293 cells cotrans-
fected with HLA-DRB1*0101 as well as with different hu-
man Ii constructs (24). These constructs encoded either
wild-type Ii, containing the original CLIP sequence, or an
Ii variant in which CLIP was replaced either by the
DRB1*0101-restricted peptide HA307–319 of the influenza
hemagglutinin or by its mutated variant in which Lys316 had
been replaced by His (HA(K H); see legend to Fig. 4 for
sequences). In the Ii-HA307–319 transfectants, the vast major-
ity of DR1 molecules have been shown to present different
length variants of the artificially introduced HA peptide se-
quence in their peptide binding grooves (24).
As shown in Fig. 4 A, all three 293 transfectants were ab-
solutely comparable in presenting Ni to T913, and the ex-
tent of this activation was similar to Ni responses induced
by DR1-expressing human B cells (Fig. 3 B). Ni specificity
of the reaction is demonstrated by the lack of responses in
the absence of NiSO4 (Fig. 4 B). In experiments not shown
here we demonstrated that transfectants expressing either
one of the two HA peptide variants, but not CLIP, both
effectively stimulate DR1-restricted human T cell clones
induced by HA307–319. In this context it is worth noting that
unlike the results of Romagnoli et al. (10), these reactions
were not inhibited by the addition of Ni, even when the
His-containing mutant peptide was presented.
His81 in the DR1   Chain, A Possible Contact Site for
Nickel. As shown above, Ni reactivity of the SE9/T913
TCR is restricted by human HLA-DR molecules encoded
by a variety of different DR alleles (Fig. 1 B) and is not af-
fected by the nature of DR-associated peptides (Fig. 4).
Therefore, we assumed that a Ni coordination complex
Figure 3. Effects of fixation and antigen pulsing on Ni presentation by
APC. 2   104/well JESTHOM B cells were fixed or not with 0.05% glu-
taraldehyde for 45 s at room temperature in RPMI without FCS and used
for presentation of Ni to clone SE9 or hybridoma T913. (A) Proliferation
of SE9. (B) IL-2 production by T913.   , in absence,   , in presence
of 10 4 M NiSO4 (clone SE9) or 2.5    10 4 M NiSO4 (hybridoma
T913).    for unfixed and    for fixed APCs. (C) APCs, fixed or un-
fixed, were either untreated (open bars) or pulsed (solid bars) with 10 3 M
NiSO4 for 1 h, washed, and then coincubated with SE9 cells. Control
cultures (gray bars) contained 10 4 M NiSO4 in the medium.
Figure 4. Peptide-independent presentation of Ni to hybridoma T913.
5   104/well T913 cells were incubated with 2.5   10 4 M NiSO4 (A) or
without Ni (B) in the presence of graded numbers of different 293 trans-
fectants as APCs, and IL-2 production was determined as described in
Materials and Methods. APCs were either untransfected (293 Contr) or
transfected with HLA-DR1 plus human Ii construct (Ii-CLIP). In two
cell lines, the CLIP sequence of Ii was replaced either by the hemaggluti-
nin peptide 309–317 (Ii-HA309–317) or by a HA mutant in which K316 was
replaced by H (Ii-HA(K H)). The core peptides presented by the re-
spective DR1-expressing cells are: CLIP, MRMATPLLM; HA309–317,
YVKQNTLKL; HA(K H), YVKQNTLHL.T
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might bridge conserved amino acid side chains of the
HLA-DR   chain with hypervariable amino acids of the
TCR   chain. The lack of Ni presentation by HLA-DR53
(Fig. 1 C) pointed to histidine in position 81 of the DR  
chain because DR53 is the only one of all DR alleles
tested (Fig. 1 C) in which the highly conserved His81 is
missing. Using L cells transfected either with wild-type
DRB1*0101 or with DR1 harboring point mutations re-
placing His81 by Ala, Asp, Glu, or Tyr, we found (Fig. 5 A)
that mutations of His81 to Ala, Asp, or Glu completely
eliminated the presentation of Ni whereas mutation to Tyr
strongly reduced, but did not eliminate reactivity. This re-
sult is not due to major structural distortions in the mutated
DR1 molecules because the DR1-restricted human T cell
clone HACoH8, specific for the hemagglutinin peptide
HA309–317, responded to its antigen in the presence of APCs
expressing either wild-type DR1 or DR1 molecules carry-
ing the various mutations in position 81 (Fig. 5 B).
Antigen Contacts within the TCR Hypervariable Sequences.
As demonstrated above, the Ni reactivity of the SE9/T913
receptor, although largely defined by its   chain (19), does
not resemble a superantigen-like activation via the genom-
ically defined VA22 sequence (Fig. 2). Therefore, to deter-
mine antigen contact sites within the T913   chain we in-
troduced a series of defined point mutations into all of its
hypervariable regions, including N-nucleotide determined
amino acids of the CDR3 loop. Table I depicts the amino
acid sequences of the three hypervariable regions in single
letter code and indicates the point mutations introduced
by PCR technology. Unexpectedly, and unlike results of
TCR mutations in other systems (29), most of these muta-
tions do not, or only partially, reduce TCR reactivity to Ni
(Figs. 6 and 7). Replacement of Lys51 by Ser in CDR2 had
already been shown not to affect Ni recognition (19). Here
we show that Ala mutations of the two aspartic acids in
positions 53 and 54 (Fig. 6) also did not impair TCR spec-
ificity, making antigen contacts via the CDR2 loop rather
unlikely.
The effects of CDR3 mutations are summarized in Fig.
7, A and B. These mutations included an elongation of
CDR3  by insertion of Ala between positions 92 and 93,
an Ala mutation of Thr95, and Ala, Phe, or His mutations
of Tyr94 (Table I). As shown in Fig. 7 A, CDR3 elongation
had absolutely no effect on Ni reactivity and the exchange
of Thr95 for Ala only partially impaired the reaction. How-
ever, mutations of Tyr94 to Ala (Fig. 7 A), Phe, or His (Fig.
7 B), completely abolished antigen reactivity of the recom-
bined TCR.
For CDR1, Fig. 7 C reveals that exchange of Thr27 for
Ala did not affect Ni recognition at all and even the Gly28
to Pro mutation, probably inducing a notable sterical alter-
ation of the CDR1 loop, resulted in only partial reduction
of reactivity. However, mutation of Tyr29 to Ala com-
pletely destroyed the reactivity for Ni (Fig. 7 C). A Tyr to
Phe mutation was not tested in this position, but replace-
Figure 5. Effects of His81 mutation in DRB1*0101 on Ni and peptide
presentation. (A) Ni-specific IL-2 production of T913 in the presence of
L cells (DAP-3) transfected with DR1 wild-type ( ) or different His81
mutants of the DR1   chain (as indicated in the figure). The small but
significant response to the H-Y mutant ( ) was repeated in several inde-
pendent experiments. (B) Proliferative response of the DR1-restricted,
hemagglutinin-specific T cell clone HACoH8 to HA309–317 peptide on the
different DAP transfectants. Untransfected DAP cells served as control
APCs in both experiments (A and B).
Table I. Point Mutations in the TCR   Chain of Hybridoma T913
CDR1 CDR2 CDR3
a.a. positiona 25 48 92
AV22 wild-typeb TATGYPS KATKADDKL G YTGTASKLT
AV22 mutatedc - - A - - - - - - - S - -  -  - - A - - - - -- - - - -
- - - P - - - - - - - - A A - -  - - A - - - - - - -
- - - - A - - -  - A - - - - - - - -
- - - - H - - -  - H - - - - - - - -
aPosition of first amino acid in each of the CDR sequences. CDR1, CDR2, and CDR3 are as previously defined (reference 47).
bAmino acid sequences in single letter code. Targets for point mutations in bold.
cAmino acid exchanges in 11 individual TCR   mutants. Dots indicate identity with wild-type sequence.T
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ment of Tyr29 by His left the TCR reactivity surprisingly
unaltered (Fig. 7 D). Hence, antigen contact is clearly me-
diated by Tyr29 and its functional replacement by His points
toward a direct involvement of Ni in this contact.
In this context it is important to note that all mutated
TCR   chains effectively paired with the T913   chain
and the resulting TCR were expressed well on the surface
of transfected hybridomas (unpublished data). Regardless of
their reactivity or nonreactivity to Ni, all TCR transfec-
tants were strongly activated by the VB17-reactive super-
antigen SEB (unpublished data).
Discussion
HLA-restricted    T cells with specificity for Ni ions
have been isolated from peripheral blood as well as from
skin lesions of Ni-allergic patients (20, 30–32) and are re-
garded as essential elements in nickel-contact dermatitis
(33). The finding that Ni blocked MHC-restricted T cell
recognition of a His-containing peptide has lead to the as-
sumption that Ni-specific T cells recognize complexes of
Ni with HLA-associated peptides (10). This rather indirect
evidence was supported by our observation that some T
cell clones reacted to Ni in the context of their respective
HLA restriction element on one type of APC, but not on
others (28). More recently, Lu et al. (34) demonstrated the
requirement of particular (though not yet identified) pep-
tides for presentation of Ni to one of our previously de-
scribed AV1/BV17  T cell clones (ANi2.3). It appears
from these data that Ni-induced epitopes for T cells may,
indeed, be formed by a complex of Ni ions with selective
MHC-associated peptides in a hapten-like fashion. The
same study also revealed a significant contribution of His81
in the   chain of HLA-DR52 in forming a Ni/MHC/pep-
tide epitope for clone ANi2.3. However, although His81 is
conserved in most HLA-DR   chains, clone ANi2.3 is se-
lectively restricted to only one DR allele (34, 35). This
might be related to the restrictive requirements concerning
the sequences of DR-associated peptides (34) as well as to
the previously described requirement for an Arg-Asp motif
in the CDR3  loop of the ANi2.3 TCR (35). As in the
case with peptide-specific TCR, the receptor of clone
ANi2.3 will recognize its specific epitope on only a small
fraction of MHC molecules expressed on APCs, a number
even more reduced by the very low Ni concentrations
available in vivo.
However, such hapten-like interaction with MHC–pep-
tide complexes is clearly not the only way for Ni to activate
T cells. Here we describe clone SE9 (or hybridoma T913)
as an example of a quite different type of TCR–Ni–MHC
interaction. This receptor reacts to Ni independently of the
nature of MHC-associated peptides (Fig. 4) or of the pre-
senting HLA-DR allele (Fig. 1). Essential antigen contact
sites had previously been shown to localize to the   chain
of the SE9 TCR (19) and antigen presentation by process-
ing inactive APCs pointed to Ni ions as part of the anti-
genic epitope (Fig. 3). We have identified the conserved
His81 residue in HLA-DR   chains as a major contact site
for the SE9 TCR. The fact that the same residue is essential
for Ni presentation to clone ANi2.3 (34) strongly points to
His81 in HLA-DR   chains as a major coordination site for
Ni. The lack of peptide participation in Ni presentation
and the involvement of the conserved His81 may explain
the promiscuous DR restriction of clone SE9 (Figs. 4 and
5). His81 has been recognized as a site for Zn coordination
Figure 6. Ni responsiveness of a CDR2 -mutated T913 receptor.
Comparison of wild-type (T913 wt) and mutated TCR transfectants
stimulated with L-DR1 cells in the absence (dotted bars) or presence
(solid bars) of 2   10 4 M NiSO4. Secreted IL-2 was determined as de-
scribed in Materials and Methods. D53 and D54 in CDR2  were replaced
by alanines in the mutant. Refer to Table I for sequences.
Figure 7. Essential tyrosines in CDR1 and CDR3 of the T913  
chain. Ni-induced IL-2 responses of T913 as compared with transfectants
mutated in CDR3 (A and B) or CDR1 (C and D) of their TCR  
chains. L-DR1 cells were used as APC. (A) CDR3 mutated by Ala inser-
tion between positions 92 and 93 ( A) or Ala replacements of T95 (T95-A)
or Y94 (Y94-A). (B) Exchange of Y94 in CDR 3 for Phe (Y94-F) or His
(Y94-H), fixed concentration of 2   10 4 M NiSO4. (C) CDR1 mutated
by Ala replacements of T27 (T27-A) or Y29 (Y29-A), or by Pro exchange
for G28 (G28-P). (D) Exchange of Y29 in CDR1 for His (Y29-H). All trans-
fectants expressed comparable amounts of TCR and regardless of their re-
sponses to Ni reacted strongly to stimulation with SEB (not depicted).
For TCR sequences refer to Table I.T
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in the context of Zn-dependent superantigens (23, 36–38).
However, the finding that it participates in direct presenta-
tion of metal ions such as Ni to DR allele-specific as well as
to DR-promiscuous Ni-reactive T cells is of particular in-
terest in the context of metal allergies. His81 is potentially
one of the central attachment sites for allergenic Ni
epitopes. Epitopes involving additional Ni coordination
sites on DR-associated peptides would be more likely re-
stricted to defined DR alleles, like the one recognized by
clone ANi2.3, whereas peptide-independent clones such as
SE9 would tend to be DR promiscuous.
The two clones further differ in that Ni-epitopes specific
for clone SE9 (Fig. 3), but not those for clone ANi2.3 (35),
are lost by washing of Ni-treated APCs. Again, this might
be explained by the different role of peptides in epitope
formation. Although Lu et al. (34) presented evidence for
stable Ni–MHC coordination complexes involving His81 as
well as peptide-determined amino acids, we found no pep-
tide contribution to SE9-specific epitopes and, hence,
probably fewer coordination sites on the DR surface. In
fact, we not only were unable to prepulse APC with Ni for
clone SE9 (Fig. 3), but also prepulsing with Ni of the T
cells, i.e. SE9 or T913, did not mediate reactivity (unpub-
lished data). Thus, neither APCs nor the SE9 TCR alone
express enough coordination sites to bind Ni tightly
enough to prevent its dissociation in the absence of surplus
Ni2  in the medium. Therefore, we assume that only
short-lived and normally unproductive complexes of the
SE9/T913 TCR with HLA-DR provide a sterically perfect
arrangement of amino acids (including His81) to accommo-
date Ni in a stable coordination complex. In that sense we
envisage Ni like a bolt that may connect two parts only
during a state of accurate positioning, requiring its perma-
nent presence in the surrounding medium.
Concerning the role of the TCR   chain in this com-
plex, we excluded a superantigen-like interaction via germ-
line-determined sequences of the AV22 element (Fig. 2).
Ala mutations within the three   chain hypervariable re-
gions identified two absolutely essential Tyr residues: one
in position 29 of the germline-encoded CDR1 common to
all AV22 sequences, and the other in the N-nucleotide–
determined position 94 of the CDR3, which is unique to
SE9 (Fig. 7 and Table I). Interestingly, the crystal structure
of a TCR/HA307–319–HLA-DR1 complex (39) reveals close
contacts between residue Pro29 in the TCR CDR1  loop
and the His81 in the HLA-DR1   chain helix. The fact that
our SE9 TCR reacts to Ni on the very same HA307–319–
HLA-DR1 complex suggests a similar orientation, includ-
ing close proximity between the TCR    chain residue
Tyr29 and His81 in HLA-DR1.
The potential role of tyrosine residues as coordination
sites for Ni in our TCR–MHC complex is corroborated by
several additional observations. On the one hand, Tyr29
could be replaced by His, probably the best chelator of Ni,
without any loss of specificity (Fig. 7 D). On the other
hand, the exchange of Tyr94 by Phe destroyed reactivity,
indicating that not the hydrophobic properties of the aro-
matic ring, but rather the p-hydroxy group of Tyr deter-
mines Ni specificity. Finally, the only mutation of His81 in
the DR   chain that left the Ni-presenting properties at
least partially intact was a change to Tyr (Fig. 5).
Even though Tyr is not generally regarded as a ligand
for Ni, it has been reported as a coordination partner for
Cu in bacterial RNase (40). Moreover, in the Ni complex
of bacterial urease two of six Ni coordination sites are oc-
cupied by oxygens of water molecules (41, 42). The more
acidic OH group of Tyr would thus certainly appear as a
possible electrophilic partner in a complex. However, a
definitive decision as to whether the identified amino acids
in TCR and MHC indeed serve as coordination sites for
Ni or rather are involved in protein–protein interactions
can only be made on the basis of a crystal structure of the
complete complex.
No specificity could be assigned to the CDR2 loop of
the T913   chain (Fig. 6). Even though position 51 of sev-
eral TCR   chains has been reported to be essential for
MHC contacts (43, 44), Lys51 in the SE9   chain has been
shown not to be required for Ni reactivity (19). Similarly,
Ni specificity was not impaired by mutation of Asp53 and
Asp54 in CDR2 (Fig. 6), although aspartic acid has been de-
scribed to be involved in metal-mediated superantigen
binding (38) as well as in the binding site for Ni in human
serum albumin (45, 46).
All together, our findings reveal the TCR of clone SE9
as an example of a so far unpredicted possibility for anti-
gen-specific and MHC-restricted T cell activation. Metal
ions, and possibly other low molecular weight compounds
as well, may form and stabilize intramolecular bridges be-
tween TCR and MHC, independent of the primary struc-
ture of MHC-associated peptides. Most superantigens
achieve a similar connection by bridging nonpolymorphic
MHC regions to V   family–specific sequences of the
TCR. In the SE9 TCR, in contrast, Ni ions require an
N-region–determined Tyr in the   chain CDR3 loop, i.e.,
within the idiotypic TCR sequences. The flexibility of
such interactions is stressed by our finding that introduction
as well as removal of the structural constraints of proline
residues within the CDR1 or CDR3 loops was well toler-
ated, and that even elongation of CDR3 by one amino
acid did not affect Ni reactivity (Fig. 7).
We detected these mechanisms due to the exceptional
features of clone SE9, particularly the dominance of its
TCR   chain in determining specificity. It is well conceiv-
able that other clones might use both   and   chains of
their TCR to form similar peptide-independent com-
plexes, however, their identification would be extremely
more difficult. Relating to Ni allergy, the impact of such
types of TCR is apparent. APCs present significantly more
Ni epitopes to peptide-independent than peptide-depen-
dent T cells, a difference further increased for clones like
SE9 recognizing Ni on different HLA-DR alleles. Even if
such receptors represent a minority within the Ni-reactive
repertoire, their effectiveness and amplifying properties in
skin responses to Ni might be significant. The question
whether the proposed model also applies to the allergic
cross-reactivities to other metals remains unanswered be-T
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cause clone SE9 did not cross-react to Cu, Pd, Co, nor Cr
(unpublished data).
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